Arih.Found.Hsg. (531381)

Fast Grower

Score breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Current Price₹255.85
Market Cap₹254.97 Cr
P/E Ratio14.87
ROCE19.52%
ROE20.76%
Dividend Yield0%
Profit Growth78.51%
Debt/Equity
Sales Growth96.75%
52-Week Range₹780 — ₹1,288
SectorRealty
Book Value₹181.6

Strengths

Concerns

AI Analysis

At first glance, Arih.Found.Hsg. looks like the kind of compounder I like: a real-estate developer earning a 20.76% return on equity and 19.52% return on capital. The latest quarter shows ₹102 Cr of sales and ₹20 Cr of net profit, roughly a 20% margin. Sales grew 96.75% and profit grew 78.51%, so the business is running hot. At ₹255.85, the P/E is 14.87 and P/B is 1.41 against book value of ₹181.60. A PEG of 0.17 is extraordinarily low—if those growth numbers are representative. But Graham taught me to treat high growth with suspicion. One quarter and one year do not make a durable franchise. Real estate is a cyclical, capital-hungry business, and I see no durable moat in the figures: no pricing power, no brand metrics, no recurring revenue. The Piotroski F-score of 7/9 is encouraging, but dividend yield is zero, so shareholders rely entirely on price appreciation. The biggest red flag is the data itself: the 52-week range is ₹780 to ₹1,429.95, yet the current price is ₹255.85. That is impossible unless there has been a corporate action, a data error, or a collapse I cannot evaluate from these figures. I cannot value a company properly with contradictory price history. Debt/Equity and promoter holding are also N/A, leaving me blind on leverage and owner alignment. The price-to-book of 1.41 offers some margin of safety if book value is real and liquidation is solid, but real estate book values can be sticky. On the reported numbers, this has the shape of a Fast Grower, but I would not commit capital before that discrepancy is resolved. Numbers attract; verification decides.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer